Xilio Therapeutics Inc (XLO)
1.14
+0.06
(+5.56%)
USD |
NASDAQ |
May 17, 16:00
1.14
0.00 (0.00%)
Pre-Market: 20:00
Xilio Therapeutics Cash from Operations (Quarterly): -10.50M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -10.50M |
| December 31, 2023 | -13.43M |
| September 30, 2023 | -13.37M |
| June 30, 2023 | -16.57M |
| March 31, 2023 | -25.25M |
| December 31, 2022 | -18.22M |
| September 30, 2022 | -19.91M |
| Date | Value |
|---|---|
| June 30, 2022 | -16.76M |
| March 31, 2022 | -20.84M |
| December 31, 2021 | -17.16M |
| September 30, 2021 | -20.72M |
| June 30, 2021 | -20.14M |
| March 31, 2021 | -22.73M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-25.25M
Minimum
Mar 2023
-10.50M
Maximum
Mar 2024
-18.12M
Average
-18.22M
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| Gilead Sciences Inc | 2.219B |
| FibroGen Inc | -59.29M |
| Avalo Therapeutics Inc | -6.202M |
| IGM Biosciences Inc | -42.42M |
| AEON Biopharma Inc | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 0.954M |
| Free Cash Flow | -53.87M |
| Free Cash Flow Per Share (Quarterly) | -0.3762 |
| Free Cash Flow Yield | -171.1% |